Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Obradovic, Marko ^a   Lal, Arun ^a   Liedgens, Hiltrud ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Chronic pain; Cost effectiveness; Cost utility; Health economics; Health technology assessment; Quality of life; Tapentadol; Utility

Indexed keywords

OXYCODONE; TAPENTADOL;

ADULT; ANXIETY DISORDER; CHRONIC PAIN; CONSTRUCT VALIDITY; DEPRESSION; DISEASE SEVERITY; EUROQOL 5; FEMALE; HEALTH STATUS; HUMAN; KNEE PAIN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF CARE; SHORT FORM 6; SOCIAL INTERACTION; VALIDITY; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

AGED; CHRONIC PAIN; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC;

EID: 84879469842     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-110     Document Type: Review

References (31)

1. Rustoen T, Wahl AK, Hanestad BR, Lerdal A, Paul S, Miaskowski C. Prevalence and characteristics of chronic pain in the general Norwegian population. Eur J Pain 2004, 8:555-565. 10.1016/j.ejpain.2004.02.002, 15531224.
2. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006, 10:287-333. 10.1016/j.ejpain.2005.06.009, 16095934.
3. Sjogren P, Ekholm O, Peuckmann V, Gronbaek M. Epidemiology of chronic pain in Denmark: an update. Eur J Pain 2009, 13:287-292. 10.1016/j.ejpain.2008.04.007, 18547844.
4. Langley P, Muller-Schwefe G, Nicolaou A, Liedgens H, Pergolizzi J, Varrassi G. The impact of pain on labor force participation, absenteeism and presenteeism in the European Union. J Med Econ 2010, 13:662-672. 10.3111/13696998.2010.529379, 21034378.
5. Langley P, Muller-Schwefe G, Nicolaou A, Liedgens H, Pergolizzi J, Varrassi G. The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization. J Med Econ 2010, 13:571-581. 10.3111/13696998.2010.516709, 20815688.
6. Langley PC. The prevalence, correlates and treatment of pain in the European Union. Curr Med Res Opin 2011, 27:463-480. 10.1185/03007995.2010.542136, 21194390.
7. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006, 10:127-135. 10.1016/j.ejpain.2005.01.014, 16310716.
8. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010, 96:5-21. 10.1093/bmb/ldq033, 21037243.
9. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the evaluation of health care programmes 2005, Oxford: Oxford University Press, Third edition.
10. Brazier J, Longworth L. NICE DSU technical support document 8: an introduction to the measurement and valuation of health for NICE submissions report by the Decision Support Unit 2011, NICE, http://www.nicedsu.org.uk/TSD8%20Introduction%20to%20MVH_final.pdf.
11. The EuroQol Group.EuroQol-a EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990, 16:199-208. The EuroQol Group.EuroQol-a.
12. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108. 10.1097/00005650-199711000-00002, 9366889.
13. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21:271-292. 10.1016/S0167-6296(01)00130-8, 11939242.
14. Lange B, Kuperwasser B, Okamoto A, Steup A, Haufel T, Ashworth J, Etropolski M. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010, 27:381-399. 10.1007/s12325-010-0036-3, 20556560.
15. Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van HI, Steup A, Lange B, Rauschkolb C, Haeussler J. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010, 30:489-505. 10.2165/11533440-000000000-00000, 20586515.
16. Buynak R, Shapiro DY, Okamoto A, Van HI, Rauschkolb C, Steup A, Lange B, Lange C, Etropolski M. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010, 11:1787-1804. 10.1517/14656566.2010.497720, 20578811.
17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
18. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
19. Bellamy N. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol 2002, 29:2473-2476.
20. Sogaard R, Christensen FB, Videbaek TS, Bunger C, Christiansen T. Interchangeability of the EQ-5D and the SF-6D in long-lasting low back pain. Value Health 2009, 12:606-612. 10.1111/j.1524-4733.2008.00466.x, 19900258.
21. Barton GR, Sach TH, Avery AJ, Doherty M, Jenkinson C, Muir KR. Comparing the performance of the EQ-5D and SF-6D when measuring the benefits of alleviating knee pain. Cost Eff Resour Alloc 2009, 7:12. 10.1186/1478-7547-7-12, 2720915, 19615052.
22. Harrison MJ, Davies LM, Bansback NJ, McCoy MJ, Verstappen SM, Watson K, Symmons DP. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res 2009, 18:1195-1205. 10.1007/s11136-009-9539-2, 2761817, 19777373.
23. Whitehurst DG, Bryan S. Another study showing that two preference-based measures of health-related quality of life (EQ-5D and SF-6D) are not interchangeable. But why should we expect them to be?. Value Health 2011, 14:531-538. 10.1016/j.jval.2010.09.002, 21315635.
24. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13:873-884. 10.1002/hec.866, 15362179.
25. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2004, 12:1061-1067.
26. Bryan S, Longworth L. Measuring health-related utility: why the disparity between EQ-5D and SF-6D?. Eur J Health Econ 2005, 6:253-260. 10.1007/s10198-005-0299-9, 15968563.
27. Grieve R, Grishchenko M, Cairns J. SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur J Health Econ 2009, 10:15-23. 10.1007/s10198-008-0097-2, 18327677.
28. Tsuchiya A, Brazier J, Roberts J. Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. J Health Econ 2006, 25:334-346. 10.1016/j.jhealeco.2005.09.003, 16271783.
29. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, Clarke AE, Gignac MA, Anis AH. Not all "quality-adjusted life years" are equal. J Clin Epidemiol 2007, 60:616-624. 10.1016/j.jclinepi.2006.09.006, 17493521.
30. McDonough CM, Tosteson AN. Measuring preferences for cost-utility analysis: how choice of method may influence decision-making. Pharmaco Economics 2007, 25:93-106.
31. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011, 20:1727-1736. 10.1007/s11136-011-9903-x, 3220807, 21479777.